SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

Never Miss a Story

Sign Up For Weekly Top Stories

 

More Industry Headlines

More Pseudomonas found at Prince George's Hospital Maryland facility investigating link between fatalities and deadly bacteria

Joint Commission presents clinical engineering survey updates and advice at CEAI Emphasizes new accreditation matrix and hand hygiene

Researchers propose bundled payment model for mammography Aligning incentives through mammo's established practice parameters

Wearable PET helmet may allow for imaging patients in motion Uses one-tenth of the conventional PET radiation dose

Yearly low-dose CT lung cancer screening is important for those at high risk Those with initial negative tests have higher mortality rates 1 and 2 years later

Most U.S. citizens would participate in precision medicine initiative: survey Young, educated people in particular

A look inside EMR and telehealth integration American Well discusses its telehealth enterprise system

Toshiba to develop boron neutron capture therapy (BNCT) system Company retained heavy particle business after selling medical unit to Canon

Researchers use fMRI to discover biomarkers for assessing Parkinson’s treatments A possible milestone on the road to a cure

Defibrillators rarely on deck for out-of-hospital cardiac arrest Researchers aim to improve access to AEDs for the general public

Will CMS revise its coverage policy for new PET agents?

by Loren Bonner , DOTmed News Online Editor
The Centers for Medicare and Medicaid Services is in the process of reconsidering its coverage determination for PET radiopharmaceuticals outside of the four it currently reimburses. Stakeholders feel it's important to simplify the process for assessing and approving new PET imaging agents for reimbursement, particularly in light of several new ones coming down the pipeline. Many of these new agents will evaluate myocardial perfusion, as well as the pathophysiology of Alzheimer's disease and Parkinson's disease.

"To go indication by indication on all these new agents we expect to hopefully be approved over the next few years will be a bit cumbersome," said Frederic Fahey, president of the Society of Nuclear Medicine and Molecular Imaging (now SNMMI, formerly SNM).

Story Continues Below Advertisement

Streamline Your Radiology Workflow with RamSoft's PowerServer RIS/PACS

The PowerServer RIS/PACS is a single database application, essential to reducing redundant work, limiting manual data entry, and increasing consistency throughout healthcare practices. Click to learn how it will help you improve patient care and more.



SNMMI, in conjunction with the Medical Imaging and Technology Alliance, American College of Radiology, Council on Radionuclides and Radiopharmaceuticals, and World Molecular Imaging Society, are backing this request to remove a second layer of approval outside the FDA's. Discussions have been ongoing for the past year with CMS, and a formal letter was sent to the agency at the end of March.

CMS has a national coverage determination in place denying reimbursement for PET agents outside of its approved list.

"Once you've gone through the rather rigorous FDA process including showing efficacy, you've done a pretty decent job of showing the indications that are being recommended for that agent," said Fahey.

The letter that was submitted to CMS from the five agencies goes on to say that recent advances in imaging and CMS' past experience with PET coverage no longer support a clinical rationale for a national noncoverage policy for new PET agents that have undergone FDA review and approval.

"In my mind, the old way may have been reasonable for FDG. FDG is a pretty non-specific agent. It goes a lot of different places and is used for many different things. But I think as we move forward into molecular imaging, more targeted and hopefully more specific imaging for a particular patient, the indications are probably not going to be as broad and wide," said Fahey.

CMS is accepting public comments until Aug. 10 to determine whether to cover remaining uses of PET.

Related:


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2016 DOTmed.com, Inc.
ALL RIGHTS RESERVED